Mobile App Click here to download our Mobile App for iOS or Android
Not a member? Sign up for free!

Can We Improve Functioning In Our Patients With Schizophrenia?

Webinar | September 26, 2018 12:00 pm to 1:00 pm ET
You must be logged in to register for PsychU events. Log In

Not a member? Sign up for free!

Join us as we continue our efforts towards improving the future of mental health care through information, discussion, and collaboration.
Sign up today for instant access to all PsychU offerings. Membership is free!

Join PsychU


Virtual Forum: Can We Improve Functioning In Our Patients With Schizophrenia?

Location: Online Via

Clinicians are tasked daily with making informed decisions regarding patients. During this Virtual Forum, Greg Mattingly, MD, and Ralph Aquila, MD, will discuss how treatment of individual patients with schizophrenia can be optimized for effective control of symptoms while minimizing side effects. They will examine the differences in antipsychotic receptor binding profiles, their side effects, and the impact that these can have on patient functioning and goal achievement on their way to recovery.

Speakers are paid consultants to Otsuka Pharmaceutical Development & Commercialization, Inc.

View Flyer (PDF)

Event Speakers

Greg Mattingly, MD
Featured Speaker

Greg Mattingly, MD, current serves as an Associate Clinical Professor at Washington University School of Medicine in St. Louis, MO, where he teaches psychopharmacology courses for the third year medical students. He is principal investigator in clinical trails for Midwest Research Group in Weldon Spring, MO, is a founding partner of St. Charles Psychiatric Associates, and serves on the board of Headway House, a community support program for individuals with chronic mental illness. He also serves on the board of directors for the American Professional Society of ADHD & Related Disorders (APSARD) and is a certified evaluator for the NFL regarding ADHD and head concussions. He has been a principal investigator in over 200 clinical trials focused on ADHD, anxiety disorders, major depression, bipolar disorder, and schizophrenia.

Dr. Mattingly received his MD at Washington University. He is a board certified in adult and adolescent psychiatry and is a Diplomat of the National Board of Medical Examiners. Having served on numerous national and international advisory panels, Dr. Mattingly has received awards and distinctions for clinical leadership and neuroscience research.

Ralph Aquila, MD
Featured Speaker

Ralph Aquila, MD, currently serves as Medical Director of Fountain House, Inc., the Director of the Sidney R. Baer Jr. Center in New York, NY, and Chief Executive Officer for the Center of Reintegration, Inc. He is listed as author or co-author of publications addressing: mortality and weight gain in individuals with serious mental illness; rehabilitation alliances; and treatment outcomes for individuals with schizophrenia

Dr. Aquila received his MD from the University of Bologna, completed his psychiatric residency at St. Luke-Roosevelt Hospital, and completed a public psychiatry fellowship at the Columbia University College of Physicians & Surgeons. He is board certified in psychiatry.

Julleah Johnson, PhD

Julleah Johnson, PhD, serves as a Senior Medical Science Liaison for Otsuka Pharmaceutical Development & Commercialization, Inc.

The registration for this event is now closed. For more information about our live event registration process, please read the Live Event Eligibility Requirements